Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atlas Crest Investment Corp. IIACII.U · Entity 126082 | Director | February 03, 2021 | February 04, 2021 |
| MediWound Ltd.MDWD · Entity 296 | Director | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atlas Crest Investment Corp. II
Report date February 03, 2021 · Filed February 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-03 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the registrant's registration statement on Form S-1 (File No. 333-251893) (the "Registration Statement") under the heading "Description of Securities--Founder Shares," the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, at the time of the registrant's initial business combination, on a one-for-one basis, subject to certain adjustments described therein and have no expiration date. F2: The reporting person has an indirect pecuniary interest in shares of Class B common stock of the registrant through membership interests in Atlas Crest Investment II LLC, over which the reporting person does not have voting or dispositive control. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the registrant's registration statement on Form S-1 (File No. 333-251893) (the "Registration Statement") under the heading "Description of Securities--Founder Shares," the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, at the time of the registrant's initial business combination, on a one-for-one basis, subject to certain adjustments described therein and have no expiration date.
F2: The reporting person has an indirect pecuniary interest in shares of Class B common stock of the registrant through membership interests in Atlas Crest Investment II LLC, over which the reporting person does not have voting or dispositive control.
MediWound Ltd.
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,283 |
Ending reported balance
After 2026-06-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-01 · Purchase · Acquired 1,730 · Balance 20,476 Row 2 · 2026-06-01 · Purchase · Acquired 10 · Balance 20,486 Row 3 · 2026-06-01 · Purchase · Acquired 1,797 · Balance 22,283 |
| Ordinary sharesSEC Table I · non-derivative | Direct | 750 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 750 F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Series A WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $13.48 · Expires 2026-11-28 | Direct | 6,534 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,534 |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.25 · Expires 2030-06-29 | Direct | 14,285 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 14,285 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52 · Expires 2031-06-15 | Direct | 1,607 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 1,607 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $14.42 · Expires 2032-05-16 | Direct | 5,357 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 5,357 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2033-05-30 | Direct | 5,900 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 5,900 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2034-02-26 | Direct | 7,542 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 7,542 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.54 · Expires 2035-02-11 | Direct | 5,600 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 5,600 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2036-03-04 | Direct | 6,250 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 6,250 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Archer Aviation Inc.
Report date September 16, 2021 · Filed September 21, 2021
Section 16 reporting ended · disclosed 2021-09-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 11:30 UTC | MediWound Ltd. MDWD · Entity 296 | PurchaseOrdinary Shares | 1,797 | $14.00 | $25,149.02 |
DisclosureSEC source: 0001178913-26-003036 · zk2635475.xml · nonDerivative · entry 3 Fox David Morton · CIK 0001829578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,283 Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 11:30 UTC | MediWound Ltd. MDWD · Entity 296 | PurchaseOrdinary Shares | 10 | $14.23 | $142.30 |
DisclosureSEC source: 0001178913-26-003036 · zk2635475.xml · nonDerivative · entry 2 Fox David Morton · CIK 0001829578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,486 Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 11:30 UTC | MediWound Ltd. MDWD · Entity 296 | PurchaseOrdinary Shares | 1,730 | $14.23 | $24,609.25 |
DisclosureSEC source: 0001178913-26-003036 · zk2635475.xml · nonDerivative · entry 1 Fox David Morton · CIK 0001829578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,476 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.